论文部分内容阅读
目的探讨厄贝沙坦联合苯磺酸氨氯地平治疗糖尿病合并高血压伴高尿酸血症患者的疗效。方法 2008年2月—2013年2月选择73例糖尿病合并高血压并伴有高尿酸血症的患者,患者依照个体化原则进行降糖治疗,待血糖控制达到临床控制标准后。厄贝沙坦组给予厄贝沙坦片口服治疗,具体剂量为150 mg,1次/d;氨氯地平片组给予苯磺酸氨氯地平片5 mg,1次/d;联合用药组给予厄贝沙坦片口服治疗150 mg配合苯磺酸氨氯地平片5 mg,1次/d。3组患者均进行6个月的治疗。结果联合用药组及厄贝沙坦组治疗后血尿酸水平较治疗前均有明显降低,差异有统计学意义(P<0.05)。在治疗前后血压变化的比较上,治疗后3组患者血压较治疗前均有明显的降低(P<0.05),血压有一定的控制效果。结论厄贝沙坦联合苯磺酸氨氯地平治疗糖尿病合并高血压伴高尿酸血症的治疗作用好,临床效果显著,厄贝沙坦能在降压的同时降低血尿酸,更好的保护肾功能
Objective To investigate the efficacy of irbesartan and amlodipine besylate in the treatment of patients with diabetes mellitus complicated with hypertension and hyperuricemia. Methods From February 2008 to February 2013, 73 patients with diabetes mellitus complicated with hyperuricemia were selected. Patients were treated with hypoglycemic treatment according to the principle of individualization until the blood sugar control reached the clinical control standard. Irbesartan group given irbesartan tablets oral treatment, the specific dose of 150 mg, 1 / d; amlodipine tablets group given amlodipine besylate tablets 5 mg, 1 / d; combination group given Irbesartan tablets oral treatment of 150 mg with amlodipine besylate tablets 5 mg, 1 time / d. All three groups were treated for 6 months. Results The levels of serum uric acid in the combination group and the irbesartan group were significantly lower than those before treatment, the difference was statistically significant (P <0.05). Before and after treatment of blood pressure changes in comparison, the three groups after treatment, blood pressure were significantly lower than before treatment (P <0.05), blood pressure have a certain control effect. Conclusion Irbesartan combined with amlodipine besylate in the treatment of diabetes with hypertension and hyperuricemia has good therapeutic effect and clinical effect is remarkable. Irbesartan can lower blood uric acid while lowering blood pressure and better protect the kidney Features